OMOP Common Data Model and OHDSI Analytic Standards

What it is

The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) is an open, person-centric relational schema that transforms heterogeneous observational health databases — administrative claims, EHR, registries — into a single, consistent structure with standardized field definitions and standardized concept vocabularies (a unified terminology layer mapping ICD, SNOMED, RxNorm, CPT/HCPCS, LOINC, NDC, and dozens more to shared "standard concepts"). It is maintained by OHDSI (Observational Health Data Sciences and Informatics), a non-profit, open-science collaborative, and is paired with an analytic-standards stack: ATLAS (a web tool for cohort/phenotype definition and study design), HADES (validated R packages for population-level effect estimation, patient-level prediction, and characterization), the ACHILLES/Data Quality Dashboard tooling for data characterization and quality, and the Book of OHDSI as the canonical methods reference. Crucially, OMOP/OHDSI is not a reporting checklist (like STROBE, RECORD-PE, or CHEERS) and not a risk-of-bias instrument (like ROBINS-I): it is a data-and-methods standardization framework whose value is reproducibility, executable study specifications, and network-scale evidence generation.

When to use

Reach for OMOP/OHDSI when (a) a study must run identically across multiple databases or sites — a distributed/federated network study where code travels to the data and only aggregate results return; (b) you want an executable, machine-readable study specification (phenotype + analytic settings) that another team can rerun and audit, supporting regulatory or HTA reproducibility expectations; (c) you are conducting large-scale comparative effectiveness, safety surveillance, characterization, or patient-level prediction and want methods (propensity scores, negative-control calibration, large-scale diagnostics) baked into validated tooling; or (d) you are building reusable phenotype libraries that must map consistently across coding systems. Decision rule: choose OMOP/OHDSI when standardization, reproducibility, and multi-database portability are first-order requirements. For a single-database, bespoke analysis with idiosyncratic variables, the ETL cost of converting to the CDM may not pay off, and a native-schema analysis (still governed by the relevant reporting guideline, e.g., RECORD-PE/HARPER) can be the simpler, defensible choice. OMOP/OHDSI is a complement to — never a substitute for — those reporting and design guidelines.

What it requires

Operationally, conformance and good practice demand: (1) ETL with documented provenance — every source code mapped to a standard concept, with a maintained source-to-CDM specification; (2) data-quality and fitness-for-use assessment before analysis (Data Quality Dashboard checks for conformance, completeness, plausibility; ACHILLES characterization), because standardized structure does not guarantee fitness for a given question; (3) transparent, shareable phenotype/cohort definitions with explicit entry/exit events, inclusion logic, and — critically — phenotype validation (the CDM standardizes codes, not clinical truth); (4) explicit time-zero / index-event logic and observation-period anchoring in the cohort definition; (5) pre-specified estimands and confounding control (new-user/active-comparator cohorts, large-scale propensity scores) executed through HADES; (6) attrition reporting via the standardized cohort-diagnostics/attrition outputs; and (7) empirical bias control and diagnostics — negative-control calibration of p-values and confidence intervals, equipoise/covariate-balance checks, and pre-registration of the study package — which the OHDSI methodology elevates from optional sensitivity analysis to a default expectation.

When NOT to use — limitations and common misapplications

OMOP/OHDSI standardizes data and code; it does not confer causal validity. Converting a database to the CDM and running ATLAS does not make a confounded comparison unconfounded, nor a poorly validated phenotype accurate — the standardized concept set still inherits every error of the source coding. Common failure modes: (i) treating a successful ETL as evidence of fitness-for-use and skipping data-quality/phenotype validation; (ii) information loss during ETL — source-specific nuance (lab units, free-text, payer-specific benefit structure, Medicare Advantage vs FFS claims completeness) that is flattened or dropped when mapping to standard concepts, silently biasing downstream cohorts; (iii) over-trusting ATLAS "rule-based" phenotypes as validated when they have only face validity; (iv) assuming network heterogeneity (different databases give different answers) is noise rather than a signal about generalizability or residual bias; (v) using OMOP/OHDSI as if it replaced a reporting guideline — a manuscript built on OMOP still must satisfy STROBE/RECORD-PE, an HTA dossier still needs CHEERS for any economic component, and a PASS still follows ENCePP/HARPER. Mistaking the data standard for a quality or reporting standard is the cardinal error.

How it maps to this catalog

OMOP/OHDSI is the standardized substrate; the concepts in this catalog supply the methodological content it operationalizes. Fitness-for-use assessment → fit-for-purpose-data-assessment-rwe and database-feasibility-attrition-funnel-rwe. Phenotype/cohort definition and validation → diagnosis-phenotype-algorithm-1ip-2op-time-window-rwe and claims-outcome-algorithm-ppv-sensitivity-rwe. Design and time-zero alignment → target-trial-emulation and active-comparator-new-user (ATLAS cohorts are the natural place to encode the new-user/active-comparator structure). Confounding control → high-dimensional-propensity-score-hdps-rwe (the OHDSI large-scale PS is the network-ready analogue). Estimand specification → estimands-ate-att-intercurrent-events-rwe and estimand-analysis-traceability-rwe. Attrition → attrition-and-loss-to-follow-up-rwe. Empirical bias control, a defining OHDSI practice → empirical-calibration-negative-controls-rwe, negative-control-outcomes-rwe, and negative-control-exposures-rwe. Data-source caveats that ETL must preserve → medicare-ffs-ma-commercial-claims-differences-rwe and claims-analysis.

Applied note (claims/EHR/registry)

In claims, the ETL must preserve enrollment/eligibility spans (the OMOP `observation_period`) faithfully, since "absence of a code" is only interpretable against continuous observability; Medicare Advantage person-time, which lacks fee-for-service claims, can masquerade as a clean washout if the ETL does not flag it. In EHR, drug orders vs administrations vs linked dispensings map to different OMOP domains and must be chosen deliberately for exposure definitions, and visit-driven capture means observation periods are inferred, not given. In registries, rich severity/staging often has no clean standard concept and is the first casualty of mapping — validate that the CDM representation still answers the question before trusting network output.